Nutraceuticals in heart failure patients

Nutraceuticals in heart failure patients

Author information

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; Heart Centre, The Alfred Hospital, Melbourne, Australia. Electronic address:
National Heart Foundation of Australia, Melbourne, Australia.
Centre for Health Services Research and Cardiovascular Research Group, School of Population Health, University of Western Australia, Perth, Australia.
Department of Cardiovascular Medicine, Flinders Medical Centre & Flinders University, Adelaide, Australia.
Department of Cardiology, Austin Health, Melbourne, Australia; School of Nursing and Midwifery, Faculty of Health, Deakin University, Melbourne, Australia.
Heart Centre, The Alfred Hospital, Melbourne, Australia,; Department of Medicine, University of Melbourne, Melbourne, Australia.
St Vincent's Hospital, Victor Chang Cardiac Research Institute, University of New South Wales, Sydney, Australia.
Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital, Sydney, Australia; University of Sydney, Sydney, Australia.
Department of Cardiology, Westmead Hospital, Department of Medicine, University of Sydney, Department of Medicine, University of New South Wales.
Department of Cardiology, Royal Brisbane and Women's Hospital, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia; Faculty of Science, Health, Education and Engineering, University of Sunshine Coast, Australia; Faculty of Health, Queensland University of Technology, Brisbane, Australia.



Nutraceuticals are pharmacologically active substances extracted from vegetable or animal food and administered to produce health benefits. We recently reviewed the current evidence for nutraceuticals in patients diagnosed with heart failure as part of the writing of the Australian Guidelines for the prevention, diagnosis and management of heart failure.


A systematic search for studies that compared nutraceuticals to standard care in adult patients with heart failure was performed. Studies were included if > 50 patients were enrolled, with ≥ 6 months follow up. If no studies met criteria then studies < 50 patients and < 6 months follow up were included. The primary outcomes included mortality/survival, hospitalisation, quality of life, and/or exercise tolerance. Iron was not included in this review as its role in HF is already well established.


Forty studies met the inclusion criteria. The strongest evidence came from studies of polyunsaturated fatty acids, which modestly decreased mortality and cardiovascular hospitalisations in patients with mostly New York Heart Association (NYHA) II and III heart failure across a range of left ventricular ejection fraction. Co-enzyme Q10 may decrease mortality and hospitalisation, but definite conclusions cannot be drawn. Studies that examined nitrate rich beetroot juice, micronutrient supplementation, hawthorn extract, magnesium, thiamine, vitamin E, vitamin D, L-arginine, L-carnosine and L-carnitine were too small or underpowered to properly appraise clinical outcomes.


Only one nutraceutical, omega-3 PUFA, received a positive recommendation in the Australian heart failure guidelines. Although occasionally showing some promise, all other nutraceuticals are inadequately studied to allow any conclusion on efficacy. Clinicians should favour other treatments that have been clearly shown to decrease mortality.

Older Post

Powered by Shopify